B

    Barinthus Biotherapeutics plc (BRNS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.70
    -0.05 (-6.61%)

    Market Cap: $30.49M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(16/22)
    Avg Surprise
    +32.79%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.26
    Range$-0.27 - $-0.25
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.29-11.5%
    60d ago$-0.29-11.5%
    30d ago$-0.29-11.5%
    7d ago$-0.25+3.8%
    Current$-0.26
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.11 - $-0.08
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.26---
    Jun 26
    		$-0.26$-0.28+7.14%Beat+50.0%
    Mar 26
    		$-0.14$-0.28+50.00%Beat+71.4%
    Dec 25
    		$-0.27$-0.39+29.82%Beat-33.7%
    Sep 25
    		$-0.24$-0.39+38.46%Beat-14.3%
    Jun 25
    		$-0.52$-0.29-79.31%Miss-20.9%
    Mar 25
    		$-0.49$-0.36-36.11%Miss-22.5%
    Dec 24
    		$-0.20$-0.37+45.38%Beat+55.1%
    Sep 24
    		$-0.21N/A+52.27%Beat+43.2%
    Jun 24
    		$-0.43$-0.41-4.88%Miss+30.6%
    Mar 24
    		$-0.40$-0.61+34.43%Beat+16.7%
    Dec 23
    		$-0.45$-0.50+10.00%Beat+21.1%
    Sep 23
    		$-0.37$-0.55+32.73%Beat-268.2%
    Jun 23
    		$-0.62$-0.59-5.08%Miss-244.2%
    Mar 23
    		$-0.48$-0.58+17.24%Beat-785.7%
    Dec 22
    		$-0.57$-0.42-35.71%Miss-50.0%
    Sep 22
    		$0.22N/A+142.31%Beat+269.2%
    Jun 22
    		$0.43$-0.40+207.50%Beat+167.2%
    Mar 22
    		$0.07N/A+122.58%Beat+103.7%
    Dec 21
    		$-0.38$-0.58+34.48%Beat+99.6%
    Sep 21
    		$-0.13N/A+56.67%Beat-103.9%
    Jun 21
    		$-0.64$-0.59-8.47%Miss+99.2%
    Mar 21
    		$-1.90$-2.11+9.95%Beat+97.6%
    Dec 20
    		$-92.90N/AN/ABeat-
    Sep 20
    		$3.32N/AN/ABeat-
    Jun 20
    		$-75.31N/AN/ABeat-
    Mar 20
    		$-80.20N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.77EV/EBITDA-6.67x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-52.40%ROIC-70.97%
    Financial Health
    Debt/Equity0.03xInterest Coverage-796.09x
    Current Ratio5.54xQuick Ratio5.54x
    Trading Statistics
    Beta-0.39Avg Volume48.23K
    52-Week High$1.8352-Week Low$0.51

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.66
    SMA 20$0.62
    SMA 50$0.62
    SMA 200$0.66
    EMA 10$0.67
    EMA 20$0.64
    EMA 50$0.63
    EMA 200$0.71

    MACD

    Line: 0.03Signal: 0.01Hist: 0.02

    ADX

    ADX: 18.6+DI: 25.3-DI: 9.6

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down12.0
    PSAR$0.60

    Bollinger Bands

    Upper Band$0.73
    Lower Band$0.51
    %B Position3675%(Upper)
    Band Width0.84

    RSI (14-Day)

    Neutral
    60.1

    Momentum Oscillators

    Stoch %K83.4
    Stoch %D88.4
    Williams %R-30.1
    ROC (10d)17.4%
    Momentum0.10
    CCI (20d)151.3
    MFI (14d)62.7

    Volatility Measures

    ATR (14d)$0.05(7.2%)
    StdDev (20d)0.06
    Hist Vol68.7%(High)

    Volume Flow

    VWAP$0.72
    OBV75.4M
    AD Line-41.1M
    CMF (20d)-0.482

    Volume Metrics

    Avg Vol (20d)48.9K
    Vol Ratio3.9x(High)
    VWMA (20d)$0.63

    Pivot Points

    R3$0.81
    R2$0.78
    R1$0.76
    Pivot Point$0.73
    S1$0.71
    S2$0.68
    S3$0.66

    Advanced Oscillators

    TSI18.57
    Ultimate Osc54.6
    KST87.34

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$-9,173,000$14.97M$0$0$5.37M$0
    Cost of RevenueN/A$854,565$907,686N/A$2.02M$2.04M$69,000$1.49M$1.47M$1.43M$1.45M$1.47M
    Gross ProfitN/A$-854,565$-907,686N/A$-2,024,681$-2,041,809$-69,000$14.97M$-1,469,000$-1,429,000$3.92M$-1,465,000
    Operating Expenses$11.02M$8.25M$8.50M$15.07M$23.32M$20.60M$23.32M$24.35M$18.29M$16.91M$19.99M$16.11M
    R&D$3.92M$3.59M$3.93M$5.15M$6.61M$7.99M$9.11M$10.53M$10.97M$10.53M$5.83M$13.94M
    SG&A$7.10M$2.53M$4.58M$5.17M$15.38M$12.64M$3.37M$13.42M$7.20M$5.99M$13.62M$961,000
    Operating Income$-11,019,000$-9,105,712$-9,411,383$-15,066,000$-23,324,000$-20,600,000$-23,390,000$-9,380,000$-18,286,000$-16,914,000$-19,988,000$-16,105,000
    Interest Income$343,000$350,000$406,000$472,000$523,000$556,000$637,000$631,000$635,000$775,000$571,000$196,000
    Interest Expense$14,000$12,978$12,981$13,000$12,000$13,000$12,000$17,000$12,000$12,000$7,000$7,000
    Income Before Tax$-10,622,000$-5,689,448$-11,259,708$-14,642,000$-21,151,000$-19,680,000$-20,588,000$-8,132,000$-16,950,000$-15,557,000$-18,110,000$-14,713,000
    Income Tax Expense$-23,000$-164,723$-172,750$-71,000$-25,000$-22,000$3,000$-3,000$-7,000$-37,000$-820,000$-603,000
    Net Income$-10,580,000$-5,521,729$-11,073,977$-14,566,000$-21,124,000$-19,648,000$-20,540,000$-8,114,000$-16,931,000$-15,489,000$-17,293,000$-14,072,000
    EBITDA$-8,932,000$-4,821,905$-10,339,041$-13,428,000$-19,138,000$-17,633,000$-19,148,000$-6,640,000$-15,471,000$-14,115,000$-16,668,000$-13,232,000
    EBIT$-10,608,000$-5,676,470$-11,246,727$-14,629,000$-21,139,000$-19,667,000$-20,576,000$-8,115,000$-16,938,000$-15,545,000$-18,103,000$-14,706,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BRNS

    News

    Barinthus Biotherapeutics Announced Transfer or Voluntary Withdrawal of Listing

    Barinthus Biotherapeutics (BRNS) announced its intention to withdraw and delist its ADSs from Nasdaq following a UK scheme effective September 3, 2026. Trading is expected to halt before September 3, after which the combined company's stock will list on Nasdaq under the ticker CLYD. This decision was formally communicated to Nasdaq on August 24, 2026.

    TradingView•8/25/26•
    Bearish

    Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

    Barinthus Biotherapeutics plc announced an update on its proposed all-stock combination with Clywedog Therapeutics, Inc. The Scheme Exchange Ratio has been determined at 0.111, and the scheme of arrangement is expected to be effective on September 3, 2026. Following the merger, Barinthus Bio ADSs will cease trading on Nasdaq, and the combined entity, renamed Clywedog Therapeutics Holdings, Inc., will trade under the ticker symbol "CLYD."

    GlobeNewswire•8/25/26•
    Somewhat-Bearish

    Barinthus Biotherapeut reports Q2 2026 net loss $10.6M, cash $59.6M; VTP-1000 MAD data due Q4 2026

    Barinthus Biotherapeutics reported a Q2 2026 net loss of $10.6 million and held $59.6 million in cash. The company completed enrollment for the VTP-1000 Phase 1 AVALON trial's multiple ascending dose portion, with topline data expected in Q4 2026. A proposed combination with Clywedog is progressing, with an anticipated closing in H2 2026 and the combined entity to be renamed Clywedog Therapeutics Holdings.

    TradingView•8/6/26•
    Neutral

    Barinthus Biotherapeutics plc. 2026: Revenue ($9.78M), Net income ($10.58M), EPS ($0.26) — 10-Q Summary

    Barinthus Biotherapeutics plc. (BRNS) reported a narrower comprehensive loss in the 2026 quarter, driven by cost reductions and pipeline reprioritization towards immunology and inflammation programs. The company also completed enrollment for a Phase 1 clinical trial and entered a merger agreement with Clywedog, with the combined entity to be renamed CLYD. Barinthus projects its current cash resources will fund standalone operations for at least 12 months.

    TradingView•8/6/26•
    Somewhat-Bullish

    Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

    Barinthus Bio announced its second quarter 2026 financial results and provided updates on corporate developments, including the progressing proposed combination with Clywedog Therapeutics Inc. The company completed enrollment for the Phase 1 AVALON trial of VTP-1000 for celiac disease, with topline data expected in Q4 2026, and anticipates completing the merger with Clywedog in the second half of 2026. Financial highlights show cash, cash equivalents, and restricted cash of $59.6 million as of June 30, 2026, and a net loss of $10.6 million for the quarter.

    The Manila Times•8/6/26•
    Neutral

    Frequently Asked Questions About BRNS

    Does BRNS pay dividends?
    Barinthus Biotherapeutics plc (BRNS) does not currently pay a regular dividend.
    What is BRNS's market cap?
    Barinthus Biotherapeutics plc (BRNS) has a market capitalization of $30.49M with a current stock price of $0.70.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In